Aribio Co Ltdis A Clinical Stage Biotechnology Company Located In Seongnamsouth Koreawith Additional Offices In The United Statesthe Company Specializes In Developing Innovative Therapies For Neurodegenerative Diseasesutilizing Its Proprietary Aridda C Platformthis Platform Integrates Ai Technology With Reverse Engineering To Enhance Drug Development Processes Aribio S Flagship Product Is Ar1001An Investigational Oral Treatment For Early Alzheimerae S Diseasethe Company Has Secured Exclusive Marketing Rights For Ar1001 In South Korea Through A Partnership With Samjin Pharmaceuticalvalued At 100 Billion Krwadditionallyaribio Has Licensed The Marketing Rights For Ar1001 In China For A Deal Worth Up To $770 Million Usdwhich Includes Milestone Payments And Royaltiesthrough Its Strategic Partnershipsaribio Aims To Expand Its Market Reach And Address Significant Unmet Medical Needs In Neurodegenerative Diseases
